Annovis Bio, Inc.

Annovis Bio, Inc. Annual Report: A Look at Their Year (Fiscal Year Ending December 31, 2025)

Considering an investment in Annovis Bio, Inc.? This summary provides a clear, jargon-free overview of the company's performance over the past year, helping you understand its operations and financial standing.

Business Overview

Annovis Bio is a clinical-stage biotechnology company that develops treatments for neurodegenerative diseases like Alzheimer's and Parkinson's. Their core strategy centers on ANVS401, their lead drug candidate, which aims to prevent neurotoxic protein formation by inhibiting their translation. As a "Non-accelerated filer" and "Smaller reporting company," Annovis Bio benefits from reporting flexibilities typical of emerging biotechs. This status often suggests a higher risk-reward profile for investors. The company primarily focuses on research and development, including preclinical studies and clinical trials.

Financial Performance

For the fiscal year ending December 31, 2025, Annovis Bio, as a pre-revenue clinical-stage company, generated no significant revenue from product sales. Capital raises primarily funded their operations. The company reported a net loss of approximately $35.0 million, primarily due to substantial research and development (R&D) expenses of approximately $28.5 million as they advanced clinical trials. General and administrative expenses comprised the remaining costs. The significant R&D spending highlights ongoing clinical trial activities.

Risk Factors

Investing in Annovis Bio involves significant risks, typical of the biotechnology sector. Key risks include:

• Uncertainty of Clinical Trial Outcomes: Even promising early data may not lead to successful later-stage trials or regulatory approval.
• Regulatory Hurdles: Substantial regulatory hurdles exist, and ANVS401 is not guaranteed FDA approval.
• Intense Competition: Larger pharmaceutical companies with greater resources pose intense competition.
• Reliance on Future Capital Raises: The company's reliance on future capital raises to fund extensive R&D efforts poses a dilution risk for existing shareholders.
• Other Risks: These include intellectual property protection, dependence on third-party manufacturers and clinical research organizations, and the highly volatile nature of biotechnology stock prices.

Management Discussion (MD&A Highlights)

Annovis Bio's clinical pipeline made significant progress this past year. A key achievement was successfully completing the Phase 2/3 clinical trial for ANVS401 in early Alzheimer's disease. Preliminary data showed promising trends in cognitive improvement and biomarker modulation. This positive outcome positions the company for potential discussions with regulatory bodies about its path to further development.

However, the company faced challenges, including delays in patient enrollment for its Parkinson's disease trial due to unforeseen external factors. These delays pushed back expected data readouts by several months. Increased competition in the neurodegenerative disease space also required continuous innovation and strategic positioning of its lead candidate. Management continues to focus on efficiently deploying capital to advance its clinical programs.

Financial Health

Annovis Bio reported cash and cash equivalents of approximately $45.0 million as of December 31, 2025. This represents a decrease from $80.0 million at the end of the prior fiscal year, reflecting a significant cash burn rate primarily from R&D activities. The company estimates this cash position will fund operations for approximately 12-18 months, requiring future capital raises to continue development beyond this period. Annovis Bio carries no significant long-term debt, maintaining a relatively clean balance sheet. As of March 12, 2026, 28,355,262 shares of common stock were outstanding. The total market value of common stock held by non-affiliates was estimated at $36.1 million as of June 30, 2025.

Future Outlook

Annovis Bio plans to advance ANVS401 towards a potential Phase 3 trial initiation in Alzheimer's disease by late 2026, contingent on regulatory feedback and securing additional funding. The company also aims to complete the Phase 2 trial for ANVS401 in Parkinson's disease by mid-2026, with data expected shortly thereafter. Annovis Bio continuously monitors the evolving scientific understanding and regulatory landscape for neurodegenerative diseases, adapting its development plans accordingly. While the market for Alzheimer's and Parkinson's treatments is vast, it remains highly competitive and subject to significant scientific and regulatory scrutiny. Future success depends on positive clinical trial results, successful regulatory interactions, and the ability to secure necessary capital.

Competitive Position

The biotechnology industry, especially in neurodegenerative diseases, is highly competitive and rapidly evolving. Annovis Bio competes with large pharmaceutical companies that have established market presence and substantial financial, technical, and human resources. It also competes with other biotechnology firms developing similar or alternative treatments. Competitive factors include:

• The efficacy, safety, and tolerability of product candidates
• The timing and scope of regulatory approvals
• The availability of reimbursement
• The ability to attract and retain qualified personnel

Annovis Bio's competitive strategy centers on ANVS401's unique mechanism of action, which aims to address the underlying pathology of neurodegenerative diseases. Its progress through clinical development helps differentiate the company in this challenging market.